AssayIndex
Contributing laboratory

Medutest

Fast turnaround and the widest compound acceptance, at unit mass resolution rather than high resolution. 934 reports in the index — 14.2 % of the total.

934 reportsgradient 25 minUnit-resolution MSrepeatability 0.26 pp
Section 1

Identification and method basis

Laboratory
Medutest
Short code in this index
Medutest
Location
Ljubljana, Slovenia
Founded
2020
Reports contributed
934
Share of index
14.2%
Purity gradient
25min
Mass resolution
Unit resolution (single quadrupole)
Stated turnaround
2–5 business days
Measured offset vs reference
+0.070 pp
Within-lab repeatability
0.26pp

Medutest is the fastest of the six laboratories and accepts the widest range of submissions, including several compound classes the others decline. Both properties make it a large and useful contributor to index breadth. The trade-off is mass resolution: Medutest's identity confirmation runs on a single-quadrupole instrument at unit resolution, which is adequate for confirming that a 4,113 Da species is present and inadequate for distinguishing species that differ by 1 or 2 Da.

The consequence is specific and the index enforces it. For the compound pairs where a small mass difference is the whole question — bremelanotide vs melanotan II (1 Da), hexarelin vs GHRP-6 (14 Da), reduced vs oxidised cyclic peptides (2 Da), deamidated vs parent (1 Da) — a Medutest identity confirmation is recorded as "consistent with" rather than "confirmed", and the record page states which alternative species were not excluded. This is not a criticism of the laboratory; it is a description of what a unit-resolution instrument can and cannot do.

Measured bias is +0.08 pp on 166 paired comparisons, with the widest limits of agreement of the three high-volume labs at ±0.52 pp. The 25-minute gradient is at the index's minimum acceptable length for the acylated incretins.

Section 2

Methods offered

What a laboratory can measure decides what a record can establish. A submission that orders only purity produces a record that names nothing.

  • RP-HPLC purity (%area, 220 nm)
  • LC-MS identity (single-quadrupole, unit resolution)
  • Karl Fischer water
  • appearance and reconstitution assessment
  • endotoxin by gel-clot LAL
Section 3

What this laboratory has measured

Reports 934
Median purity reported 99.12% n=933
Index median 99.08% n=6584
Batches touched 567
05511016592.093.094.095.096.097.098.099.0100.092.00–92.25 %: n=092.25–92.50 %: n=092.50–92.75 %: n=092.75–93.00 %: n=093.00–93.25 %: n=093.25–93.50 %: n=093.50–93.75 %: n=093.75–94.00 %: n=094.00–94.25 %: n=094.25–94.50 %: n=094.50–94.75 %: n=094.75–95.00 %: n=095.00–95.25 %: n=095.25–95.50 %: n=095.50–95.75 %: n=095.75–96.00 %: n=096.00–96.25 %: n=096.25–96.50 %: n=096.50–96.75 %: n=196.75–97.00 %: n=497.00–97.25 %: n=497.25–97.50 %: n=1697.50–97.75 %: n=2297.75–98.00 %: n=3898.00–98.25 %: n=6098.25–98.50 %: n=7398.50–98.75 %: n=8498.75–99.00 %: n=9499.00–99.25 %: n=13099.25–99.50 %: n=10899.50–99.75 %: n=10699.75–100.00 %: n=193median 99.12 Purity (% area) Reports
Figure 1. Distribution of purity figures reported by Medutest. This is not a distribution of material quality — it is a distribution of what this laboratory was sent, which is a different and unrepresentative sample. Compare its shape against another laboratory's rather than its position: a short gradient compresses the left tail because unresolved species are counted into the main peak.
Most-tested compounds hereReportsMedian purity
Semaglutide10698.89
Tirzepatide8998.48
BPC-1577599.21
Retatrutide6598.36
Ipamorelin3699.38
TB-5003599.79
GHRP-63599.56
CJC-1295 (no DAC)3299.28
Semax3199.66
IGF-1 LR32898.50
SS-31 (Elamipretide)2199.69
L-Glutathione (reduced)2099.35
MK-677 (Ibutamoren mesylate)2099.61
PT-141 (Bremelanotide)1999.00
Epitalon1999.71
CJC-1295 with DAC1799.09
Section 4

Agreement with the other laboratories

Each row is a paired analysis: batches where this laboratory and another one both assayed the same physical lot. A difference on a matched pair is bias plus noise, and it is the only clean way to compare laboratories.

AgainstPaired lotsMean difference (pp)95 % limits of agreementWithin 0.5 pp
Janoshik495+0.070-0.53 to 0.6789%
PeptideMeter374+0.087-0.60 to 0.7885%
VendorInvestigate258+0.212-0.59 to 1.0273%
Nordanalyt232+0.017-0.67 to 0.7086%
Kestrel187-0.264-1.23 to 0.7069%

Positive means Medutest read higher. The full paired analysis, with its assumptions →

Section 5

Provenance of what this laboratory receives

A laboratory that mostly receives supplier-supplied samples produces a record set with a known upward pressure on it, however good its analysis is. This is a property of the submission channel and not of the laboratory.

ProvenanceReportsShareEvidentiary weight
Buyer-sourced80886.5%Strongest available evidence in this index.
Supplier-supplied707.5%Weaker evidence. Read with the caveat below.
Laboratory-retained566.0%Provenance documented, selection uncontrolled.
Section 6

Recent records from this laboratory

The 25 most recent of 934. All records from Medutest →
ReportCompoundSupplierLotQuarterPurity %Water %Recovery %ProvenanceFlagsResult
AX-2026-043179Kisspeptin-10GL BiochemGLBI-2608-N77152026-Q398.974.37Buyer-sourced1MARGINAL
AX-2026-043319BPC-157CPCCPC-2602-W16102026-Q398.822.88103.5Buyer-sourced2MARGINAL
AX-2026-042083MOTS-cHYBHYB-2606-D78582026-Q399.932.02Buyer-sourced0PASS
AX-2026-042492SS-31 (Elamipretide)HomopeptideHOMO-2604-D54842026-Q399.932.40Buyer-sourced0PASS
AX-2026-042441RetatrutideHomopeptideHOMO-2605-V47182026-Q398.934.22Buyer-sourced0PASS
AX-2026-041271LiraglutideWWBWWB-2607-X21892026-Q399.524.5797.4Buyer-sourced1MARGINAL
AX-2026-041683CJC-1295 with DACTFSTFS-{CAT}-96752026-Q398.683.4697.0Buyer-sourced0PASS
AX-2026-042784CJC-1295 (no DAC)GGPepsGGPE-2606-E12342026-Q398.274.55Buyer-sourced0PASS
AX-2026-042519SemaxHomopeptideHOMO-2605-S52272026-Q399.755.55Buyer-sourced0PASS
AX-2026-042509IGF-1 LR3HomopeptideHOMO-2607-P51312026-Q398.636.23103.0Buyer-sourced0PASS
AX-2026-042645SemaglutideSWBSWB-2602-X79052026-Q398.484.5295.2Buyer-sourced0PASS
AX-2026-041975TirzepatideAMBAMB-2603-C51122026-Q397.883.45106.9Laboratory-retained0PASS
AX-2026-041930IGF-1 LR3SinoPepSNP-2606-D46202026-Q398.545.3793.8Buyer-sourced0PASS
AX-2026-043020AdipotideMKMMKM-2606-K50122026-Q397.735.74Buyer-sourced0PASS
AX-2026-043389SermorelinWXTWXT-2608-P33872026-Q398.973.4499.6Supplier-supplied0PASS
AX-2026-043023AdipotideMKMMKM-2606-K50122026-Q397.485.56103.7Supplier-supplied0PASS
AX-2026-042127TB-500JEEPJEEP-2602-V86142026-Q399.683.55Buyer-sourced1FAIL
AX-2026-043534GHRP-2SIGSIG-2603-60312026-Q399.112.1589.8Buyer-sourced1MARGINAL
AX-2026-042004SemaglutideAMBAMB-2607-N62742026-Q397.746.45Buyer-sourced1MARGINAL
AX-2026-042526GHRP-6HJHJ-2603-R53292026-Q399.373.06Laboratory-retained0PASS
AX-2026-041429RetatrutideQYBQYB-2604-B49202026-Q398.532.6999.8Buyer-sourced1MARGINAL
AX-2026-042499IGF-1 LR3HomopeptideHOMO-2607-P51312026-Q398.485.9888.0Buyer-sourced1MARGINAL
AX-2026-042283RetatrutideTFCTFC-2608-J11562026-Q398.425.0994.5Buyer-sourced1FAIL
AX-2026-041778TB-500ASYASY-{CAT}-21672026-Q399.933.9196.2Laboratory-retained0PASS
AX-2026-043185Kisspeptin-10GL BiochemGLBI-2608-N77152026-Q398.713.71107.0Buyer-sourced1MARGINAL